AKB-6548
AKB-6548 is a pharmaceutical drug with 6 clinical trials. Historical success rate of 100.0%.
Success Metrics
Based on 6 completed trials
Phase Distribution
Phase Distribution
2
Early Stage
4
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
100.0%
6 of 6 finished
0.0%
0 ended early
0
trials recruiting
6
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
20-Week Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia
42-Day Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia
Safety and Efficacy Study for AKB-6548 in Participants With Chronic Kidney Disease and Anemia
16-Week Repeat Oral Dose Study of AKB-6548 for Anemia in Participants With End Stage Renal Disease (ESRD) Requiring Chronic Hemodialysis
Effects of Ferrous Sulfate on the Pharmacokinetics of AKB-6548
Clinical Trials (6)
20-Week Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia
42-Day Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia
Safety and Efficacy Study for AKB-6548 in Participants With Chronic Kidney Disease and Anemia
16-Week Repeat Oral Dose Study of AKB-6548 for Anemia in Participants With End Stage Renal Disease (ESRD) Requiring Chronic Hemodialysis
Effects of Ferrous Sulfate on the Pharmacokinetics of AKB-6548
Effect of AKB-6548 on the Pharmacokinetics of Celecoxib
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6